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ABSTRACT
TRANSCRIPTIONAL PROFILE OF COHESIN COMPLEX MUTATIONS IN THE
BACKGROUND OF NPM1 AND RUNX1-RUNX1T1 AML
Jacob Tiegs
Marquette University, 2022
Acute Myeloid Leukemia is a cancer of the blood, characterized by a
heterogenous mixture of disease causing mutations. Mutations of the cohesin
complex is a group of such mutations and occur alongside several other driving
mutations in the development of Acute Myeloid Leukemia. This thesis specifically
focuses on cohesin complex mutations in the context of concurrence with NPM1
mutation and the Core Binding Factor (CBF) mutation RUNX1-RUNX1T1 in three
distinct components. The first two components involved Differential Expression
Analysis (DEA) to identify significantly differentiated genes in each model,
followed by Gene Set Enrichment Analysis (GSEA) to identify Gene Ontology
(GO) terms associated with the significantly expressed genes. The third
component involved a cross analyses of the significantly expressed genes from
both the NPM1 and CBF analyses to identify genes enriched in both primary
analyses and further Gene Ontology Overrepresentation Analysis was used to
characterize the gene ontology terms shared in the identified gene set.
In the DEA of NPM1mutatant + cohesin mutant vs. NPM1 wild-type mice there
were 239 genes up-regulated NPM1-cohesin mutant model and 126 downregulated genes identified. DEA of cohesin mutant + RUNX1-RUNX1T1 vs.
cohesin wild-type RUNX1-RUNX1T1 from a cohort of pediatric and adolescent
patients revealed 212 upregulated genes and 472 downregulated significantly
differentiated genes identified.
The cross analyses of differentially expressed genes from both the NPM1 and
CBF analyses completed with an analyses for enrichment of the CBF gene set in
the NPM1 up and down regulated gene sets revealed 55 genes that were of the
core GSEA enrichment. From the 55 genes a number of GO terms were
identified from the Biological Process, KEGG and Reactome GO collections.
Network and clustering analyses further was used to identify patterns in the
representation of the Biological Process GO terms identified. The predominant
cluster was representative of GO terms involving immune, inflammatory, and
leukocyte processes. The emphasis on immune/inflammatory dysregulation from
the outcome in the analyses serves as a potential point of interest in
characterizing the functional role of the cohesin complex in future studies.
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1. BACKGROUND
1.1 Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a cancer of the blood. It is characterized
by genomic mutations that effect hematopoiesis. Specifically the disease is
classically characterized by a proliferation of immature hematopoietic stem/
progenitor cells (HSPC) with impaired capacity to differentiate into mature cell
lines.
AML represents 1% of new cancer cases and 31% of all leukemic cancer
cases. There are an estimated 20,050 new AML cases to be diagnosed in 2022.
Additionally there are an estimated 11,540 deaths from AML in 2022,
representing approximately 2% of all cancer deaths of the year (SEER, 1930).
AML is primarily found in an older population with a median age of diagnosis
being 68 years of age. The 5-year relative survival rate is 30.5% (SEER, 2022).
However, the prognosis distinctly segregates based on age, where younger
patients see overall survival rates of approximately 50% and older patients see
overall survival less than 25% (Fisher et al., 2017).
AML is characterized by the accumulation of poorly differentiated myeloid
cells in the bone marrow, as well as extending to the peripheral blood and
sometimes other organs. Associated with the expansion of this cell population
patients often present with anemia and thrombocytopenia. Common signs and

￼

2
symptoms include fatigue, anorexia and weight loss, fever, susceptibility to
infection and excessive bleeding/bruising (Heimbruch, 2022; De Kouchkovsky &
Abdul-Hay 2016).
AML is a heterogenous disease with a variable prognosis associated with
the vast landscape of mutations that can be associated with the disease.
Cytogenetic based risk stratification is a contributing factor used in determining
prognosis. A favorable prognosis is associated with cytogenetically identifiable
mutations including PML-RARA, RUNX1-RUNX1T1 and MYH11-CBFB fusions
and poor prognosis is associated with monosomy and complex alterations.
However, the majority of patient are cytogenetically normal, which is associated
with intermediate risk stratification, adding importance to additional identification
of mutations contributing to AML beyond the cytogenetic characterization (The
Cancer Genome Atlas Research Network, 2013). Broadly, the etiology of the
disease can be summarized as requiring mutations that drive two defined
pathologic changes in the clonal population. These mutations include those that
drive a proliferative advantage and mutations that lead to a block in the
differentiating capacity of the cells, commonly defined as Class I and Class II
mutations respectively. In the classical model of the disease, cells accumulate
mutations from each class, driving the leukemic transformation. Briefly
summarized Class I mutations include those in the signal transduction pathways
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including FLT3, Tyrosine Kinase Domain Mutations (TKD), K/NRAS and C-KIT.
Class II mutations include NPM1, C/EBPA and those involved in fusion
transcripts including RUNX1/ETO, CBFB/MYH11 and PML/RARA (Takahashi,
2011; De Kouchkovsky and Abdul-Hay, 2016; Gilliland, 2001).
While this classification can neatly organize these subset of mutational
drivers, it does not fully characterize the contributing mutations found in AML. In
a landmark study that set out to more broadly characterize the mutational
spectrum of AML 23 genes were identified as recurrently mutated and over 200
additional genes were found to be mutated in more than one patient. In this study
patients were identified to have on average 13 mutations, which is lower than
other cancers (ranging from ~50 to ~300 in various cancers), however in the
context of the vast landscape of identified mutations, AML is demonstrated to be
a highly heterogenous disease (The Cancer Genome Atlas Research Network,
2013; Heimbruch, 2022). The study classified the spectrum of mutations found
into nine distinct categories. The categories and relative prevalence found in the
study included transcription-factor fusions (17%), gene encoding nucleophosmin
(NPM1) (27%), tumor suppressor genes (16%), DNA-methylation–related genes
(44%), activated signaling genes (59%), chromatin-modifying genes (30%),
myeloid transcription-factor genes (22%), cohesin-complex genes (13%), and
spliceosome-complex genes (14%) (The Cancer Genome Atlas Research

￼

4
Network, 2013). Along with identifying a classification framework for the
contributing mutations to AML, this study identified a novel group of mutations in
the cohesin-complex to be associated with the disease (Heimbruch, 2022).
1.2. Cohesin Complex
This thesis is focused on cohesin-complex mutations in AML. The cohesincomplex is a ring-like multimeric protein complex composed of SMC1A, SMC3,
RAD21 and a variable STAG subunit, STAG1, STAG2 or STAG3. The canonical
function of the cohesin complex is to mediate sister chromatin cohesin and
segregation in mitosis and meiosis. Beyond its function involving sister chromatin
cohesin, the cohesin-complex has been shown to function in double-stranded
DNA damage repair and transcription regulation (Mazumdar et al,. 2015; Tsai et
al., 2017). SMC1A, SMC3 and RAD21 form the ringed structure of the complex.
During interphase the complex can be found localized throughout the
chromosomes. Specifically it has been found to be localized at active enhancers
and core promoters commonly associated with sites containing CTCF (CCTCfactor). More generally the cohesin is associated with TAD (topologically
associated domains) sites which function to create insulated neighborhoods that
act to promote DNA interactions contained within the TAD between the promoter
and distant conservative regulatory elements (CREs) resulting in regulation of
genes within the TAD. The insulated neighborhood referred to above are
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chromatin loops containing a gene and regulatory elements which are formed by
an association of CTCF-CTCF homodimers and the cohesin ring (Heimbruch,
2022; Han et al. 2021). It is worth noting that while cohesin and CTCF function
together, they are independently loaded onto the DNA and the loss of either
component leads to different effects. Additionally, cohesin association with
enhancers and promoters is not solely found at CTCF interaction sites
(Heimbruch, 2022). The functional role of cohesin in maintaining the DNA loop
structure has been shown through depletion of cohesin leading to loss of the
DNA loop structure (Heimbruch, 2022).

Figure 1. Representation of cohesin complex as a ring like structure that
associates with DNA. It acts to bring adjacent regions of DNA together to
promote transcriptional changes.
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Cohesin's role in gene regulation is directly implicated by its function in
DNA looping structure. It has been shown that cohesin loss results in variant
transcription and DNA accessibility in HSPCs (hematopoietic stem and progenitor
cells). Generally, a function of cohesin in interaction with CTCF is to organize cis
regulatory elements and promote gene silencing. Of direct interest in the context
of AML the HOXA gene cluster has been shown to have transcriptional changes
with the depletion of cohesin. The HOXA cluster has a role in driving the HSPC's
transcriptional profiles which are silenced during differentiation. The silencing
mechanism that leads to HSPC differentiation is mediated by the polysomy
repressive complex (PRC2). Depletion of cohesin has been shown to lead to
decreased PRC2 recruitment and leading to increased HOXA expression and
increased HSPC proliferation through continual expression/activation of myeloid
transcriptional factors pathways (Heimbruch, 2022; Fisher, et al. 2017). This is
one model of cohesin’s role in leukemia. Other components and implicated
pathways have also been identified.
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Figure 2. Pictorial representation of how lack of cohesin complex can lead to
transcriptional changes
Cohesin complex mutations are found in approximately 12%-13% of all
AML patients. It is additionally found in other myeloid malignancies as well (Han
et al., 2021; Thota et al., 2014; The Cancer Genome Atlas Research Network,
2013). Certain subsets of AML have been shown to have a higher association
with cohesin mutations, specifically t(8;21) AML it was found to have an
additional cohesin mutations in 20% of cases (Han et al., 2021). Cohesin
mutations were also commonly associated with NPM1 mutations (21.6%) and
FLT3/ITD mutations (21.6%) (Tsai et al., 2017). Cohesin mutations are
heterozygous, loss of function mutations. The mutations are mutually exclusive
within components of the complex with evidence showing that homozygous loss
or loss of multiple subunits leads to complete failure of the cell ability to survive.
Heterozygous, mutually exclusive mutations of the cohesin complex have been
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shown to be required to drive leukemogenesis (Han et al., 2021; Viny et al.,
2015). The prognostic significance of cohesin mutations are controversial, where
some studies have cohesin mutation have been shown to be a favorable factor
for overall survival and others have shown opposite effects. It seems that specific
subunit mutation and other associated mutations play a major role in prognosis
(Cuartero, et al., 2019; Han et al. 2021; Heimbruch, 2022).
Cohesin mutations contribute to AML through haploinsufficiency which
increases the self-renewal capacity and alters the differentiation pattern of the
HSPCs (Heimbruch et al., 2021; Fisher, et al., 2017). While all of the
mechanisms associated with cohesin mutations that drive leukemogenesis have
not been described, much progress has been made in elucidating these
mechanisms. It is worth noting that while the canonical function of cohesin is in
sister chromatid cohesin in cellular division, it has been shown that cohesin
mutated cells do not have a correlation with gross aneuploidy. Indicating that
disruption in this function of cohesin is not a driving factor in leukemogenesis
(Fisher et al., 2017). Instead, the transcriptional changes associated with cohesin
mutations have been heavily implicated in the associated pathogenesis. While
one model of the cohesin mechanism for pathogenesis has been described
above, generally transcriptional changes associated with cohesin mutant cells
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have been described as down-regulated gene sets that contain regulatory factors
required for lineage commitment in HSPCs (Viny et al., 2015).
Additionally, cohesin mutations have been shown to not have the capacity
to independently drive leukemogenesis. Instead cohesin associated AML
requires an additional cooperative mutation for leukemic development (Viny et
al., 2015). This thesis is focused on the transcriptional changes found in cohesin
associated AML in the context of two of these cooperative mutations, those being
NPM1 mutant and core-binding factor (CBF) AML.
1.3. NPM1 and Core Binding Factor (CBF)
NPM1 mutations are found in approximately 30% of all AML patients and it
has been shown that up to 57% of patients with a cohesin mutation also had a
NPM1 mutation (Heimbruch, 2022). NPM1 mutations typically result in a mis
localization of NPM1 protein from the nucleolus to the cytoplasm (NPM1c). This
mis localization has been indicated to result in an elevated expression of HOXA
and HOXB gene clusters and MEIS1, all of which have been linked to HPSC selfrenewal and myeloid leukemogenesis when over-expressed. Interestingly, the
HOXA over-expression is also a feature found in cohesin mutant AML, in both
cases the over-expression is associated with epigenetic changes to the HOXA
loci (Heimbruch, 2022; Heimbruch et al., 2021; Fisher et al. 2017).
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Additionally, the NPM1c has been shown to cause mis localization of
CTCF to the cytoplasm, which disrupts CTCF's function in insulating gene
neighborhoods and resulting in further aberrant gene expression (Heimbruch
2022; Han et al. 2021).
Core-binding factor is a heterodimeric protein composed of an alpha
subunit, responsible for binding the complex to the DNA and a beta subunit,
responsible for enhancing the alpha subunits binding capacity. The alpha subunit
is constructed of a RUNX protein (of which there are 3) and there is only a
singular beta subunit CBFB. RUNX1 (AML1) is the alpha subunit associated with
and required for hematopoiesis. The CBF AML is associated with several
chromosomal rearrangements and mutations that cause AML pathogenesis. The
most common being t(8;21) and inv(16), named RUNX1-RUNX1T1 (AML1-ETO)
and CBFB-MYH11, respectively.
CBF AMLs represent 25-30% of pediatric and 15% of adult AMLS
(Heimbruch, 2022). While this subset of AML is associated with a good
prognosis, 40% of patients are susceptible to relapse (Heimbruch, 2022).
Cohesin mutations have been found to be associated with the RUNX1-RUNX1T1
subtype in 18% to 27% of cases (Heimbruch, 2022) and is therefore are of
interest in this thesis. RUNX1-RUNX1T1 results in a oncoprotein that retains the
RUNX1 capacity to bind DNA and has the new capability to recruit repressive
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factors to the loci it binds. The repressive function of the oncoprotein results in an
inability for the cells to progress through normal myeloid differentiation
(Heimbruch, 2022).
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2. STATEMENT OF THESIS
This thesis is focused on identifying transcriptional changes in the cohesin
mutant leukemias. Specifically in the context of associated NPM1 and RUNX1RUNX1T1 mutations. The study has three components. The first two being a
reanalyzes of transcriptional data from a NPM1/cohesin mutated mouse model
and reanalyzes of transcriptional data from a collection of patients with RUNX1RUNX1T1/cohesin mutation AML. From these primary analyses differentially
expressed genes will be identified and associated enriched gene sets will be
derived. The third component of the study uses the results of the primary
analyses as hypothesis generating tools to identify similarities and differences of
the transcription changes between the NPM1/cohesin mutant model and the
RUNX1-RUNX1T1/cohesin mutant model. This third component can be
summarized as a cross-examinational query of the gene-sets identified in the
NPM1/cohesin mutant model within the RUNX1-RUNX1T1/cohesin mutant
dataset. The results of this cross-examination can be used to identify genes,
gene sets and functional pathways that may be of interest for further interrogation
to aid in the understanding of cohesin-AMLs and in the development of
treatments to this AML subset.
Throughout the body of the thesis a few different terms are used to describe the
NPM1 and RUNX1-RUNX1T1 analyses. NPM1 is referred to as the “mouse”
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analyses and the RUNX1-RUNX1T1 is referred to as “human” or “CBF”
throughout the following sections.
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3. METHODS AND RESULTS
This thesis focuses on several computational analytic techniques useful to
identifying and characterizing the transcriptional profiles generated in the body of
the work. These techniques include exploratory analyses, primarily Principal
Component Analyses (PCA), Differential Expression Analyses (DEA), Gene Set
Enrichment Analyses (GSEA), Over Representation Analysis and clustering
algorithms used to generate the networks and trees figures. Each of these
primary methodologies are reviewed below to provide background in the analytic
method prior to examination of the analyses and derived results.
The exploratory analyses is a generalized term used to describe the series
of analytic techniques used in generating general information on a datasets,
which can be used in both the final analytic results of analyses and as guides
when moving into more advanced analyses. These include frequency measures
and other descriptive statistics, as well as statistical techniques like Principal
Component Analyses (PCA). PCA is a matrix dimension reduction technique,
with the aim to reduce the number of dimensions (thought of as variables) that
the data is represented in, while maintaining the important information within the
data (variance of the observations). In the context of transcriptional analyses it
can be used as a part of the exploratory analysis process to visualize patterns in
the data, such as clustering pattern of samples. It also serves a purpose to

￼

15
identify erroneous samples, that may be flagged for removal from downstream
analyses (outliers). In brief, PCA performed on a normalized sample/variable
matrix (gene counts matrix in DEA). PCA uses the normalized matrix to calculate
a set of paired Eigenvectors and Eigenvalues. Each Eigenvector is orthogonal to
all others and each Eigenvalue represents the a portion of the total variance seen
in the starting matrix. Commonly, the two greatest Eigenvalues are selected and
associated Eigenvectors are used to visualize the transformed matrix’s data as a
two dimensional plot. The new “x” and “y” axis of the plot represent the two
generated principal components that encode the most variation within the original
matrix. A determination of relative variation between samples represented on the
plot can be made, with confidence that the variance shown is mostly
representative of all the variation in all of the variables from the starting data. The
utility in this thesis was to use PCA to determine if one set of sample with a given
condition is different than another set of samples with a different or null condition.
This difference is can often be preliminarily shown through clustering patterns
demonstrated in the PCA plot. Additionally, decisions on outliers can be made
based on erroneous clustering of the samples.
Beyond exploratory analyses, one of the core analytic component of the
thesis was Differential Expression Analyses (DEA). DEA is an analytic method
that differentiates the expression levels on each gene based on one or multiple
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conditions, in the case of this thesis the condition levels were wild type (or
psuedo-wild type) against cohesin mutant. Several DEA tools exist, and in this
thesis DESeq2, an R package, was used. The basic components of DESeq2
involves fitting a generalized linear model of the negative binomial type, with the
parameters being the mean count and dispersion estimate for each gene. The
resulting coefficient of the linear equation is the log2 fold change for the
condition. The model additionally generates test statistics for the coefficient, from
which hypothesis testing can be completed and p-values can be derived for each
coefficient of the model. The p-values generated are calculated from independent
hypothesis tests for each gene. Naturally, since each genes p-value is derived in
an independent hypothesis test from the other genes, an additional consideration
for the multiple-hypothesis testing is made. To do so the set of generated pvalues is corrected with a Benjamini-Hochberg correction to generate a new set
of adjusted p-values. The Benjamini-Hochberg procedure helps control the False
Discovery Rate (FDR), which is the rate of hypothesis tests called significant,
when actually they fail to reject the null hypothesis. By using the BenjaminiHochberg correction the number of false positives can be controlled to an
acceptable value. The set of adjusted p-values and the FDR acceptable value
are used to determine which genes are called statistically significant, and in
combination with an established log2 fold change value of biological significance

￼

17
a set of significantly expressed genes can be collected for further analyses (Love
et al., 2014).
GSEA is another analytic tool used extensively in this thesis. The GSEA
implementation used in this research was obtained from used from the Cluster
Profiler package in R. GSEA its a statistical procedure that aims to determine if
genes in a set (associated with a specific phenotype) are found in either the top
or bottom (or randomly distributed throughout) of the ranked list of genes from
the DEA (ordered by log2 fold change and including both significantly called and
non-significantly called genes), The procedure first calculates an Enrichment
Score (ES) by walking down the ranked list and for each gene the ES will
increase by one if it is in the phenotypic gene set and decrease by one if it is not
in the phenotypic gene set. The ES statistic is the maximum deviation from 0
calculated across the walk over the ranked gene set and is the correlation of the
ranked gene set with the phenotypic gene set. A p-value for each ES value from
each phenotypic set is then calculated by comparing the ES against a null ES
value distribution, generated by permutations of the phenotypic gene sets.
Finally, since ES scores are calculated for many phenotypic sets independently, a
multiple hypothesis testing adjustment is made to the calculated p-values and the
adjusted p-values are used to collect a subset of phenotypic sets significantly
enriched in the DEA ranked gene list (Subramanian et al., 2005).
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In some of the clustering analyses performed with the output of the GSEA,
the Leading-Edge subset of genes from each was used from each phenotypic
gene set. The Leading-Edge subset is the set of genes from the phenotypic gene
set that contribute most to the ES maximum magnitude. For phenotypic sets that
are enriched in the positive log2 fold change end of the ranked list this would be
the set of phenotypic genes to the left of the ES maximum magnitude measure
and for phenotypic sets that are enriched n the negative log2 fold change end of
the ranked list, this would be the set of phenotypic genes to the right of the ES
maximum magnitude measure.The output of significantly called phenotypic sets
and Leading-Edge gene sets can be used to identify biological processes that
are shown to be increased or decreased by comparison of the test conditions to
the control conditions used in the DEA (Subramanian et al., 2005).
Gene Over Representation analysis is another method used in this
analysis that is similar to GEA. This method used a hypergeometric distribution to
identify if phenotypic sets are statistically over-represented in a derived gene set
of interest in comparison to a background of all genes (potentially observed).
This method was used in this thesis in the case were a full ranked list of genes
was not available (required for GSEA), specifically as the output of Leading-Edge
genes collected from a separate GSEA application (Wu et al., 2021).
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The results of GSEA and Over Representation analysis are visualized
throughout with dot plots and tree plots of derived phenotypic sets. The dot plots
include the Gene Ratio, adjusted p-value of the ES statistic and gene count of
the phenotypic set. The Gene Ratio is the ratio of genes identified from the
phenotypic set that are in the ranked list to the total number of genes in the
phenotypic set. The tree plots reports the the adjust p-value and gene counts for
each phenotypic set, as well as performs a term-wise hierarchical clustering of
the enriched phenotypic terms using a Jaccard similarity index (Yu, n.d.).
Two additional network visualizations were generated. The first using a kmeans approach to cluster the phenotypic terms by represented genes, with a
centroid frequency value optimized for visualization. The clustered phenotypic
sets were grouped as nodes and the nodes subjected to network visualization by
a simple term-wise association to create edges. The second network analyses
simply connected Leading Edge genes to their representative phenotypic sets.
3.1. Study Design
Two RNA-sequencing datasets were used in the study. The first being
from a NPM1cA-SMC3delta/+ mouse model developed from crossed NPM1flox/+ and
SMC3flox/+ mice. The RNA-sequencing data was collected from the bone-marrow
of the four the mouse genotypes WT, NPM1cA/+, SMC3∆/+, and Double (where
double contain both NPM1 and SMC3 mutations) (Meyer et al., 2018). The
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dataset was obtained in FASTA format and were subsequently aligned to the
MM10 mouse genome using the STAR aligner v.2.7.3a. The generated BAM files
were indexed using samtools version 1.6 and a count matrix was generated
using the featurCounts tool of the subread package v.2.0.1. The
MusMusculus.GRCm38.102.gtf was used to generate the annotations of the
feature counts matrix.
The second dataset was a human RNA-sequencing dataset of CBF-AML
patients, containing both RUNX1-RUNX1T1/cohesin wild-type and RUNX1RUNX1T1/cohesin mutant genotypes. These patient samples were originally
identified and analysed by Faber et. all (Faber et al., 2016) and the resulting
dataset was obtained from the European Genome Archive (study ID
EGAS00001000349) as well as the associated metadata. The dataset was
obtained as pre-aligned BAM format files that were subsequently processed with
the featureCounts tool from the Rsubread packaged v.2.2.6. Annotations with in
the count matrix were generated from HG19. Differential Expression Analyses
was completed on both count matrices in R v.4.0.2 using the Deseq package
v1.39.0.
The output from both DEA studies were used in downstream analyses
including GSEA and clustering algorithms. The GSEA method used was obtained
from the R package ClusterProfiler package v.4.4.4. Network visualizations were
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completed with the R package Igraph v.1.3.4. All other packages used in the
analyses can be found in Supplementary Table 7.
3.2. Differential Expression Analyses
3.2.1. NPM1 with Cohesin Differential Expression Analyses
The first analysis completed was identification of differentially expressed
genes between a Double(NPM1 mutated and SMC3 mutated mice) and wild type
mice.
From the four mouse models, only the Double and wild-type were selected
for analysis as the primary goal of this analyses was to generate a list of
differently expressed genes specific to cohesin mutant + NPM1 mutant vs the
wild-type counterpart. Differential expression analysis was performed using an
adjusted p-value cut-off of 0.1 and a log2 fold change threshold of 2.
There were 239 genes up-regulated NPM1-cohesin mutant model and 126
down-regulated genes, all with an absolute fold change greater than 2.
Additionally, PCA analysis demonstrated a distinct clustering of the NPM1cohesin mutant model from the wild-type model, shown in Figure 3, along with
the MA and Volcano plot of the NPM1 DEA. A full list of significantly called
differentially expressed genes can be found in Supplementary Table 1. The list of
differentially expressed genes was further used in Gene Set Enrichment Analysis
(GSEA) independently and with the gene set collected in the second component.
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A.

B.

NPM1 PCA

NPM1 MA Plot

C.

NPM1 Volcano Plot

Figure 3. PCA plot of differentially expressed genes from the mouse NPM1SMC3 mutant (double) and wild type mouse lines (A). MA plot of the differentially
expressed genes from the NPM1-SMC3 mutant vs wild type analysis (B).
Volcano plot of the NPM1-SMC3 mutant vs wild type analysis.
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3.2.2. CBF with Cohesin Differential Expression Analyses
There were 27 patients in the CBF-AML dataset. The patients were of a
pediatric subset, with the majority of patient being in the range 6-15 years of age.
The dataset was 44% female and 56% male. All of the patients contained a
RUNX1-RUNX1T1 mutation and either no cohesin mutation, defined as WildType in this component of the study (18 patients), or at least one mutation in at
least one cohesin component (9 patients) including RAD21, SMC1A or SMC3 (3,
3, 2 patients respectively). One patient had a cohesin mutation in both SMC3 and
RAD21. Additional mutational burden was detected by Whole Genome
Sequencing. The median number of additional mutations detected in the cohort
was 4. The summary of the cohort characteristics can be found on Table 1. Of
note the SMC3-RAD21 double mutated patient had a detected additional burden
of 44, the significance of this is unknown.
PCA analysis completed, shown in Figure 4, showed an identifiable
clustering of the cohesin mutant patients, although this cluster was not cleanly
separated from the wild-type counterparts. The most variance between samples
was found in 3 of the wild-type patients from the rest of the whole cohort. Review
of the meta data on these samples revealed no indication as to reason behind
the variation and the samples were kept in analyses.
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Characteristics
Age

Sex

Cohesin
Mutations

N = 27
0-5

5 (19%)

6-10

10 (37%)

11-15

9 (33%)

16-20

2 (7.4%)

21-25

1 (2.7%)

F

12 (44%)

M

15 (56%)

RAD21

3 (11%)

SMC1A

3 (11%)

SMC3

2 (7.4%)

SMC3 RAD21

1 (3.7%)

Wild Type

18 (67%)

Median Associated Mutations
SMC3

4

SMC1A

3

SMC3 RAD21

44

RAD21

1

Wild Type

4

Table 1. Characteristics of the human cohort used in analysis including
distributions of age, sex, number of other mutations and frequency of cohesin
mutations/wild type. Median frequency of other mutations associated with each
cohesin mutation and wild type patients.
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Figure 4. PCA plot of the human cohort colored by cohesin mutation/wild type
class (A). MA plot of the human cohesin mutant vs. wild type differentially
expressed genes (B). Volcano plot of human cohesin mutant vs. wild type
differentially expressed genes.
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Differential expression analysis was performed specifically comparing the
RUNX1-RUNX1T1/cohesin mutant to the RUNX1-RUNX1T1-cohesin wild-type.
All cohesin mutations were grouped as "cohesin mutant" and there was no
differentiating of specific cohesin mutant subtypes in the DEA. There were 212
upregulated genes and 472 downregulated genes significantly differentiated with
a 0.2 adjusted p-value and fold change threshold of 1. Of note in the first mouse
model analyses a fold change threshold of 2 was used, while in this analyses a
fold change of 1 was used. This decision was based on the differentiation being
made in each analyses. In the first there would be a hypothesized large
difference in expression patterns between the NPM1/cohesin mutant model and
the mouse wild-type model, allowing a more stringent threshold fold change to
detect more significantly changed gene expression patterns. In the human cohort
analyses, the comparison is between RUNX1-RUNX1T1/cohesin-mutant and
RUNX1-RUNX1T1/cohesin-wild type. The difference in gene expression patterns
was hypothesized to be less in the comparison between both cohorts, requiring a
more lenient fold-change threshold to detect changes. In fact 0 genes were
shown to be significantly differentially expressed at a fold-change threshold of 2
and only 9 gene were significantly differentially expressed at a fold-change
threshold of 1.5 (results not shown), indicating the necessity to use a less
stringent parameter for detecting differentiated genes in this part of the analyses.
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The associated MA plot and Volcano Plot from the DEA results is shown in Figure
4. A full list of significantly called differentially expressed genes can be found in
Supplementary Table 2. The results of analyses were collected and used in the
third component of analyses.
3.3. Gene Set Enrichment Analyses
3.3.1. NPM1 and CBF with Cohesin Gene Set Enrichment Analyses
The differentially expressed gene sets collected in the prior components
were then each analyzed through Gene Set Enrichment Analyses. This analyses
was completed in R using the ClusterProfiler package. Both differentially
expressed sets were analyzed against two Gene Ontology datasets broadly
classified as Molecular Function and Biological Process. Additionally, two gene
collections from the Molecular Signatures Database (MSigDB), Hallmark and
Canonical Pathways were also reported.
In the NPM1 differentially expressed gene set, the enriched gene sets
primarily occurred in the down expressed subset of genes. The top 10
significantly enriched gene sets from each collection are shown in Figure 5 and
Figure 6 Of note the one gene set enriched in the upregulated genes belonged to
the "signaling receptor regulator activity" (ES score not shown). Among the top
enriched gene sets, RNA associated, epigenetic and those involving DNA
replication were implicated.
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NPM1

Figure 5. Top 10 GSEA plots from the mouse NPM1-cohesin mutant/wild type
differentially expressed genes for each of the Biological Process and Molecular
Function gene sets. Each line represents the enrichment score plot from each
gene set.
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NPM1

Figure 6. Top 10 GSEA plots from the mouse NPM1-cohesin mutant/wild type
differentially expressed genes for each of the Hallmark and Canonical Pathways
gene sets. Each line represents the enrichment score plot from each gene set.
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RUNX1RUNX1T

Figure 7. Top 10 GSEA plots from the human RUNX1-RUNX1T1 cohesin mutant/
RUNX1-RUNX1T1 cohesin wild type differentially expressed genes for each of
the Biological Process and Molecular Function gene sets. Each line represents
the enrichment score plot from each gene set.
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RUNX1RUNX1T

Figure 8. Top 10 GSEA plots from the human RUNX1-RUNX1T1 cohesin mutant/
RUNX1-RUNX1T1 cohesin wild type differentially expressed genes for each of
the Hallmark and Canonical Pathways gene sets. Each line represents the
enrichment score plot from each gene set.
In the CBF-AML differentially expressed gene sets, the enriched gene sets
were solely enriched within the down regulated subset. The top 10 significantly
enriched gene sets from each collection are shown in Figure 7 and Figure 8.
Among the top enriched gene sets, immune associated, leukocyte and myeloid
associated gene sets were implicated. A more expansive list of enriched gene
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sets arranged by term similarity is shown below for each NPM1 (Figure 9) and
CBF-AML (Figure 10). The expanded clustered trees of terms was only
completed for the Canonical Pathway and Biological Process collections.

NPM1

Figure 9. Top 50 most significantly identified terms of the NPM1 cohesin mutant
differentially expressed gene set derived from the Biological Process (A) and
Canonical Pathways (B) gene set collections. P-value denoted by color and
frequency of matched genes denoted by size of each associated gene terms
pointer. Gene sets are clustered by associated label terms.
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RUNX1RUNX1T1

Figure 10. Top 50 most significantly identified terms of the RUNX1-RUNX1T1
cohesin mutant differentially expressed gene set derived from the Biological
Process (A) and Canonical Pathways (B) gene set collections. P-value denoted
by color and frequency of matched genes denoted by size of each associated
gene terms pointer. Gene sets are clustered by associated label terms.
3.4. Comparison of NPM1 and CBF
Comparison of the NPM1 and CBF-AML differentially expressed gene sets
was completed in two ways. First a comparison was done through identifying
enriched gene sets found in both of the differentially expressed gene sets,
reviewed above. The second method was through GSEA analyses of the CBF-
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AML differentially expressed gene set against the NPM1 differentially expressed
up and down genes as separate gene sets.
3.4.1. Direct Comparison of NPM1 and CBF Generated Gene Sets
Using the identified enriched gene sets shown above a comparative
analyses was completed between the NPM1 (mouse) and CBF-AML (human)
enriched gene sets.
Within the human collection of enriched gene sets identified, the Biological
Process collection had the greatest frequency of identified gene sets, totally over
1000 gene sets. In the mouse collection there were fewer enriched gene sets
identified, with the most being from the Canonical Pathways and Biological
Process collections. Enriched gene sets found in both analyses had the greatest
frequency within the Biological Process and Canonical Pathways collections.
Frequencies of the mouse (NPM1), human (RUNX1-RUNX1T1) and intersecting
identified gene sets are shown in Figure 11.
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Figure 11. Frequency of identified genes for each the RUNX1-RUNX1T1 cohesin
mutant (human) (A), NPM1-SMC3 mutant (mouse) (B), and gene sets found in
both mouse and human (C) GSEA analyses. Gene collections compared include
Biological Process (BP), Cancer Sets (CAN), Cellular Components (CC),
Canonical Pathways (CP), Hallmark (HALL), Molecular Function (MF),
Transcription Factors (TF).
The top 50 most significantly enriched terms contained in both the NPM1
and RUNX1-RUNX1T1 identified sets of gene sets for the Biological Process,
Canonical Pathways, Hallmark Pathways and Molecular Function collections
were collected and clustered by term similarity. Clustered terms include those
involving immune response, interleukin and cytokine processes, and leukocyte/
myeloid specific processes from the Biological Process collection. Cell Cycle/
DNA replication, interleukin/cytokine process and immune associated process
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were detected from the Canonical Pathways. The Hallmark and Molecular
Function Collections had fewer and assorted overlapping gene sets. The
assorted clustered trees are shown in Figure 12, Figure 13, Figure 14. The full
set of GO terms can be found in Supplementary Figure 3.

Biological

Figure 12. Top 50 terms identified in from the Biological Function collection.
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Canonical

Figure 13. Top 50 terms identified from the Canonical Pathways collection.
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Figure 14. Identified gene sets from the Hallmark and Molecular Function
collections.
3.4.2. NPM1 Cross CBF Gene Set Enrichment Analyses
To evaluate the gene-to-gene similarity of the NPM1 and CBF-AML
analyses, GSEA was used with the NPM1 differentially expressed (DE) gene set
split into two, up and down DE sets and used as the query sets in a GSEA with
the CBF-AML DE set.
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Figure 15. Venn Diagram of gene to gene comparison in each of the differential
expression categories from both experiments. CBF-up includes up regulated
genes from the RUNX1-RUNX1T1 cohesin mutant analysis, CBF-down includes
down regulated genes from the RUNX1-RUNX1T1 cohesin mutant analysis,
NPM1-Up includes up regulated genes from the NPM1 cohesin mutant analysis.
NPM1-down includes down regulated genes from the NPM1 cohesin mutant
analysis.
In general comparison of gene-to-gene involvement there were 19 genes
significantly down expressed in both the NPM1 and CBF, called with the
respective significance and fold change threshold described above. There were 4
genes found to be up-regulated in the NPM1 and down-regulated in the CBF and
2 genes found to be up-regulated in both NPM1 and CBF. Only 1 gene was found
to be upregulated in CBF and down-regulated in NPM1. The associated Venn
diagram is shown in Figure 15 and list of intersecting genes can be found in
Supplementary Table 4.
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Gene ontology over-representation analyses with the Biological Process
collection was completed on the overlapping gene sets. The NPM1-up CBFdown and NPM1-down and CBF-up overlapping gene sets returned no gene
ontology terms. However, the NPM1-up and CBF-up overlapping gene set did
return 7 GO terms mainly involving biological process involved in meiosis,
meiotic division and recombination (analyses not shown). These terms were
based around the HSF2BP gene that was contained in the double up-regulated
set. This gene could be of further research as it may be involved in the
proliferative advantage seen in NPM1-cohesin mutated and CBF-cohesin
mutated cells. The over-representation analyses was not completed on the
NPM1-down CBF-down gene subgroup as GSEA was further performed to
characterize this subgroup.
GSEA was completed using the split NPM1-up and NPM1-down
differentially expressed gene sets. It was found that the CBF-AML gene set was
significantly enriched within the NPM1 (mouse) down-expressed genes (P <.001)
shown as the Enrichment Plot in Figure 16.
There were 55 core enrichment genes identified in the analyses. As these
genes contribute the most to the gene set enrichment score they were collected
for further gene ontology processing.
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Figure 16. GSEA analysis of the RUNX1-RUNX1T1 cohesin mutant (human)
differentially expressed gene set in the NPM1 cohesin mutant (mouse) down
regulated gene set.
The 55 genes identified as core enrichment genes in the GSEA analyses
were used in Gene Ontology Over-Representation Analyses with the Biological
Process, KEGG and Reactome collections (Figure 17). Forty of the genes were
found to be overrepresented in the Biological Process GO sets. The most
significantly over-represented terms generally include those involving immune
response, and myeloid activities. The full list of GO terms can be found in
Supplementary Figure 5.
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Figure 17. Dotplot of the top significantly identified gene sets through OverRepresentation analysis from the core gene sets identified in the human vs.
mouse down regulated GSEA analysis.
3.4.3 Gene Set Network Analyses
To further characterize the Gene Ontology (GO) terms associated with this
core-enrichment set a clustering analyses was performed to group the
ontological terms. The GO sets were first clustered on represented gene
similarity using a k-means cluster algorithm into 40 gene-based clusters. To
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identify the cluster for GO term similarity the top five highest frequency terms
were collected from each cluster. The clusters were then connected and mapped
as a network of associated terms. The resulting network of gene and term
mappings are shown in Figure 18 and associated term/color legend in Table 2.
The full list of GO terms, clustering gene centers and grouping terms can be
found in Supplementary Table 5.
A second network analyses approach was used to display gene
connections to individual GO sets (Figure 19). This network was constructed
through a general mapping of each gene to the GO sets it is represented in. The
GO set is represented as a colored node (of note not all GO sets are shown in
this graphic to increase readability, the GO sets not shown are still included in the
map but are represented as un-noded end points). The mapping of the GO set
nodes was determined by a K-nearest neighbor algorithm. For interpretation, the
GO sets with more shared gene will cluster closer together. Additionally, the color
of the GO set nodes were determined through representation of the top 13
identifying terms from the collection of GO sets (Table 3). Identifying terms were
manually selected as best quality describing terms. Supplementary Table 6
contains a the GO terms associated with the colored nodes.
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Figure 18. Gene based association network where terminal nodes represent
specific GO terms and internal nodes are clustered GO terms by gene similarity.
Internal nodes are clustered by term similarity. Full list of GO terms and labeling
colors are shown in Table 2 below. Generalized clustering group associations are
labeled by text.
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Table 2. GO cluster keyword terms representing 40 cluster groups and
associated network color labels.
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Figure 19. Gene to gene network across the identified GO terms. Distinct genes
represented by their symbol in text. GO terms represented by colored nodes. GO
term nodes location based on similarity of representing genes. GO node label
colors selected by top representative terms from the GO terms.
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Table 3. Representative term color labels for GO terms nodes.
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4. DISCUSSION
This thesis involved three main components in analyses. The first two
components involved differential expression analyses of a NPM1-cohesin mutant
against wild-type mouse lines as well as differential expression analysis of a
CBF-AML dataset including RUNX1-RUNX1T1 cohesin mutant patients to other
RUNX-RUNX1T1 cohesin wild type patients. The generated gene sets were
collected and used in further downstream analyses to identify Gene Ontology
sets enriched in each analyses. The third component then compared the two
primary DE analyze results to determine shared genes and GO pathways
between both analyses. This comparison was made in two ways. First through
direct comparison of GO sets resulting from the primary DE analysis and
secondly through an additional GSEA analyses searching for enrichment of the
RUNX1-RUNX1T1 cohesin mutant DE genes within the up-regulated NPM1cohesin mutated genes and down-regulated NPM1-cohesin mutated. The
RUNX1-RUNX1T1 cohesin mutated DE gene set was found to be significantly
enriched in the down-regulated NPM1-cohesin mutated genes. From this GSEA
analyses, the core enriched genes were captured and used in further GO
analyses to identify GO sets associated with this core enrichment.
In both the direct comparison of GO sets and in the overrepresentation
analysis of the GSEA core gene sets, the was a strong emphasis on down-
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regulation of GO sets involving immune/inflammatory response and leukocyte
and myeloid specific processes. These results agree with prior analyses
completed which showed cohesin having a distinct role in regulating
inflammatory processes which additionally have a role in driving cellular
differentiation in response to immune stimulation. Cohesin mutant cells have
been shown to have an acquired resistance to immune driven differentiation,
leading to increased proliferation of immature cell populations (Cuartero et
all.,2019). The identified genes and GO sets associated with cytokine and other
inflammatory mediators may represent a dysregulated gene network shared
between NPM1/CBF cohesin mutated cells that may be of interest to further
study.
There are a few directions that the results of this analyses could be further
expanded on. First, in the analytic realm an interactive graph could be developed
based on the network found in Figures 11 and 12. The underlying concept would
be to allow selective filtering by specific genes or GO terms, allowing users to
more easily identify specific network components creating a better tool for
generating hypothesis for further analyses than the current static figures.
Additionally, further studies could be conducted with cell or mouse models to
directly analyze the differential expression of RUNX1-RUNX1T1 cohesin mutant
models to a wild-type model, similar to the analyses seen with the mouse model
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and NPM1 + cohesin in this analyses. Further the comparison of driving mutation
such as RUNX1-RUNX1T1 and NPM1 to models combining the driving mutation
with a cohesin mutation could be done, as was done in a similar fashion to the
RUNX1-RUNX1T1 component of this analyses. These two potential studies could
help clarify which expression network changes are due specifically to cohesin
mutant effects, rather than changes expressed from the driving mutations. Finally
it would be beneficial to expand the set of driving mutation and cohesin mutations
analyzed to examine if the immune and inflammatory changes seen in this
analyses are consistent across more combinations of cohesin mutant AMLs.
As mentioned above cohesin mutations have been shown to be strongly
associated with impaired sensitivity to inflammatory signal driven differentiation
leading to proliferation of cohesin mutant cells. An interesting line of investigation
involves the concept that aging results in increased inflammatory signaling
followed by increased hematopoietic differentiation. As cohesin mutant cells have
a gained resistance to reacting to this inflammatory signaling, the cohesin mutant
cells have a proliferative advantage for further clonal expansion. In compliment to
this the interferon pathway is heavily deregulated in cohesin mutant cells. Studies
have shown that treatment with exogenous interferon can partially rescue the
deregulated interferon pathways, which could lead to a better response to
inflammatory signaling and potentially revive the balance of proliferation and
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differentiation in cohesin mutant cells. While in vitro study has shown potential in
use of interferon treatment in AML, clinical trials have not shown a high rate of
successful outcomes (Cuartero et al., 2019). While in this current analyses no
specific genes or networks were identified a key contributors to cohesin mutated
cells mechanism of resistance to inflammatory signaling, further examination of
the identified set of gene and pathways shown to be dysregulated in combination
with other analyses that I outlined above could lead to identification of potential
pathways that could be interrogated for future use in compliment with interferon
treatment to increase the viability of use of exogenous interferon as treatment for
AML. Specifically, when considering the inflammatory resistance as a critical
phenotype, additional KEGG and Reactome pathway analyses could be used to
with the generated gene sets to identify potential bottleneck genes that are being
dysregulated, leading to the phenotypes described. The identification of the
genes would allow a basis continue these analyses into further gene perturbation
studies,
There are a few considerations to be taken into account for this study. First
being the comparison from a mouse model used in the NPM1 study to the human
population used in the CBF-AML study. This comparison may not completely
reflect the dysregulation seen if just human or just mouse models were used.
The patients used in CBF-AML DEA component also only represent only an
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adolescent population, which could represent a different dysregulation spectrum
than found in adult CBF cohesin AML, as well as NPM1 mutations in cooccurrence with cohesin mutations are less frequently found in pediatric
populations (Heimbruch et al., 2021), so given the adolescent background
represented in the CBF-AML population used, the comparison may not be
accurately reflected in a human population. The patients also had a
heterogenous collection of additional mutations in their samples that may
represent some of the effects found in the DE analysis. Additionally, these
patients contained cohesin mutations of RAD21, SMC1A and SMC3 whereas the
NPM1 component only involved a cohesin mutation of SMC3. Further
interrogation of the identified genes and GO sets is needed to elucidate genes
with specific roles in cohesin AMLs and to identify potential treatments leading to
better outcomes for the disease.
In this study a collection of dysregulated genes and GO sets were
identified to be shared in both NPM1 cohesin mutant and CBF cohesin mutant
AMLs. This collection will help further the understanding of cohesin mutant AMLs
in two ways. First it provides a differentiation of pathways effected in RUNX1RUNX1T1 cohesin mutant AMLs to other RUNX1-RUNX1T1 AMLs. Second it
identifies pathways that are shared among cohesin mutant AMLs considering at-
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least 2 of the cooccurring mutational backgrounds found in the cohesin mutant
AML family.
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